SLC5A2 and dementia: In the intention-to-treat analysis, SGLT2 inhibitor versus DPP4 inhibitor initiation was associated with a 14% lower risk of all-cause dementia (HR [95% CI]: 0.86 [0.79–0.94]; Fig. 2C).